Ads
related to: pradaxa 150 mg side effects
Search results
Results From The WOW.Com Content Network
Dabigatran, sold under the brand name Pradaxa among others, is an anticoagulant used to treat and prevent blood clots and to prevent stroke in people with atrial fibrillation. [ 6 ][ 7 ] Specifically it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. [ 6 ]
Medical use. Direct factor Xa inhibitors include rivaroxaban, apixaban and edoxaban, and are types of direct oral anticoagulant (DOAC), which are blood thinning drugs, one of the classes of antithrombotic drugs. [4][5][6] They are commonly prescribed to treat and prevent blood clots in veins, prevent stroke and embolism in people with non ...
Idarucizumab is a non-competitive inhibitor that forms complexes with dabigatran to counteract its anticoagulant effect within minutes of administration. [8] It binds to dabigatran that is free or bound to thrombin, as well as dabigatran's active metabolites. [9] Idarucizumab is specific to dabigatran and has an affinity that is around 350 ...
For the oral anticoagulant trade named Pradaxa, see Dabigatran. Dextropropoxyphene[ 5 ] is an analgesic in the opioid category, patented in 1955 [ 6 ] and manufactured by Eli Lilly and Company. It is an optical isomer of levopropoxyphene. It is intended to treat mild pain and also has antitussive (cough suppressant) and local anaesthetic ...
Epalrestat is a carboxylic acid derivative [1] and a noncompetitive and reversible aldose reductase inhibitor used for the treatment of diabetic neuropathy, which is one of the most common long-term complications in patients with diabetes mellitus. It reduces the accumulation of intracellular sorbitol which is believed to be the cause of ...
Nilutamide is used in prostate cancer in combination with a gonadotropin-releasing hormone (GnRH) analogue at a dosage of 300 mg/day (150 mg twice daily) for the first 4 weeks of treatment, and 150 mg/day thereafter. [27][36] It is not indicated as a monotherapy in prostate cancer. [27]
Common side effects include hypoglycaemia (low blood sugar), urinary tract infections, genital infections, and volume depletion (reduced amount of water in the body). [14] Diabetic ketoacidosis is a common side effect in people with type 1 diabetes. [15] Serious but rare side effects include Fournier gangrene. [16]
[1] [17] [32] The weak CYP3A4 inhibitor ranitidine (150 mg) is predicted to increase overall exposure to daridorexant by 1.5-fold; the moderate CYP3A4 inhibitor diltiazem (240 mg) increased exposure to daridorexant by 2.4-fold; and the strong CYP3A4 inhibitor itraconazole, on the basis of physiologically-based pharmacokinetic modeling, would be ...